Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 44 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Methylnaltrexone bromide Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Tolerance and Pharmacokinetics Study of MNTX Tablets

NCT01366339
View directory record Official record
Conditions
Normal Healthy Volunteers
Interventions
Oral methylnaltrexone, Oral placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Phase 4 Interventional Results available

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

NCT00672477
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
29
States / cities
Mobile, Alabama • Laguna Hills, California • Lancaster, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Phase 4 Interventional Results available

Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

NCT00672139
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone bromide
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
26
States / cities
Mobile, Alabama • Laguna Hills, California • Lancaster, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone

NCT01367587
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IV Methylnaltrexone
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX

NCT01366378
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
methylnaltrexone
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Phase 2 Interventional

Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus

NCT01367548
View directory record Official record
Conditions
Postoperative Ileus
Interventions
IV Methylnaltrexone (MNTX), Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 2, 2026, 3:23 AM EDT
Terminated Phase 4 Interventional Results available

Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids

NCT02977286
View directory record Official record
Conditions
Constipation
Interventions
Naloxegol Oral Tablet, Placebo Oral Tablet, Docusate Sodium 100 Mg oral capsule [Colace], Senna 217 Mg Oral Tablet, Polyethylene Glycols, Bisacodyl 10 mg Suppository, Magnesium Citrate Oral Liquid Product, Methylnaltrexone
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Not applicable Interventional Results available

Compassionate Use Study of Methylnaltrexone

NCT01368562
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Methylnaltrexone
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects

NCT01366326
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
Methylnaltrexone bromide
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation

NCT00804141
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
94
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

NCT01367535
View directory record Official record
Conditions
Healthy Adults
Interventions
SC Methylnaltrexone (MNTX), IV Methylnaltrexone (MNTX), Oral Paroxetine, SC Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain

NCT00547586
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728), placebo
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Mobile, Alabama • Litchfield Park, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function

NCT01367561
View directory record Official record
Conditions
Healthy Males
Interventions
Naloxone, IV Methylnaltrexone (MNTX), Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 2, 2026, 3:23 AM EDT
Withdrawn Phase 2Phase 3 Interventional

A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

NCT04083651
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Methylnaltrexone bromide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Methylnaltrexone on GI Transit in Healthy Volunteers

NCT01055704
View directory record Official record
Conditions
Gastric Motility Disorder
Interventions
Methylnaltrexone only, Codeine only, Methylnaltrexone + codeine, Placebo + placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function

NCT01367522
View directory record Official record
Conditions
Liver Dysfunction
Interventions
SC Methylnaltrexone (MNTX)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets

NCT01366352
View directory record Official record
Conditions
Normal Volunteers
Interventions
MNTX tablet (Formulation 1), MNTX tablet (Formulation 2)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX

NCT01367483
View directory record Official record
Conditions
Healthy Male Volunteers
Interventions
IV methylnaltrexone (MNTX)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

NCT00529087
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728), placebo
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Mobile, Alabama • Sun City, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 2, 2026, 3:23 AM EDT
Completed Phase 4 Interventional Results available

Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

NCT03523520
View directory record Official record
Conditions
Constipation Drug Induced
Interventions
Methylnaltrexone Bromide 150 mg Oral Tablet, Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1, Naloxegol 25 MG Oral Tablet
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 2, 2026, 3:23 AM EDT